NCT06437951View on ClinicalTrials.gov

to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

May 31, 2025

Conditions
Erosive Gastroesophageal Reflux Disease
Interventions
DRUG

Fexuprazan Injection

20/40/80 mg

DRUG

Fexuprazan Injection placebo

20/40/80 mg

DRUG

Fexuprazan Injection_part 2

20mg

DRUG

Fexuprazan Injection_part 3

40mg

DRUG

Fexuprazan tablet

40mg

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY